Italia markets close in 2 hours 33 minutes

FTSE MIB
33.497,82
-209,39(-0,62%)
Dow Jones
39.112,16
-299,05(-0,76%)
Nasdaq
17.717,65
+220,84(+1,26%)
Nikkei 225
39.667,07
+493,92(+1,26%)
Petrolio
81,25
+0,42(+0,52%)
Bitcoin EUR
57.569,16
+475,31(+0,83%)

NBIX Oct 2024 155.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

6,70

0,00

(0,00%)

In data: 09:30AM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat